Table 5: Adverse events in patients treated with tocilizumab.

Adverse eventsPatients, (%)

Laboratory abnormalities:
 Neutropenia30 (40%)
 Thrombocytopenia2 (2%)
 Elevation of alkaline phosphatase1 (1%)
 Elevation of aminotransferases15 (20%)
Infections:
 Gastroenteritis11 (14%)
 Nasopharyngitis72 (96%)
 Upper respiratory tract infections56 (74%)
 Cellulitis3 (4%)
 Herpes outbreak6 (8%)
 Acute focal pneumonia3 (4%)
 Number of infectious AEs per patient-year2.2
Macrophage activation syndrome1 (1%)